[Tumor markers p53, sFAS, FASL, CEA and CA 19-9 in evaluating the effectiveness of surgical and pharmaco nutritional treatment of patients with gastric cancer].
The objective of this study is to develop a marker panel of abnormalities of immune regulatory systems and cell genome in patients with gastric cancer for assessment of efficacy of surgical treatment in combination with pharmaco-nutritional therapy in early postoperative period.


METHODS
Expression of p53, sFAS, FASL, CEA, and CA 19-9, nutritial status, as well as incidence of purulent-septic complications in early postoperative period were determined in 40 patients with gastric cancer (21 patients--the test group and 19 patients--the comparative group) prior to a curative surgical intervention, postoperative days 1 and 7, while the pharmaco-nutritional therapy (the test group) or partial parenteral nutrition (the comparative group) has been performed.


RESULTS
The pharmaco-nutritional therapy significantly decreases in activity of tumor suppressing genome, lymphocyte apoptosis, expression of oncology-associated markers, incidence of purulent-septic complications, as well as exacerbation risk for hypotrophy in patients with gastric cancer in early postoperative period.


CONCLUSIONS
To assess the efficacy of the surgical intervention performed in patients with gastric cancer, an expression of mutant p53 and markers of lymphocyte apoptosis (sFAS/FASL) is reasonable to be evaluated together with determination of oncomarkers (CEA and CA 19-9).
G A
GA
Bluvshteĭn
V G
VG
Lysenko
N B
NB
Zakharova
I V
IV
Kitaev
D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D018395:CA-19-9 Antigen / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000097:blood; D053222:Fas Ligand Protein / Q000097:blood; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009752:Nutritional Status; D018529:Nutritional Support / Q000379:methods*; D057947:Parenteral Nutrition Solutions; D011237:Predictive Value of Tests; D013274:Stomach Neoplasms / Q000175:diagnosis / Q000601:surgery* / Q000628:therapy; D016159:Tumor Suppressor Protein p53 / Q000097:blood; D019014:fas Receptor / Q000097:blood
D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen; C505661:FASLG protein, human; D053222:Fas Ligand Protein; D057947:Parenteral Nutrition Solutions; D016159:Tumor Suppressor Protein p53; D019014:fas Receptor